Amgen (AMGN) Lobbying Data
AMGN lobbying summary
Amgen Inc. (AMGN) has reported $115.0M in federal lobbying spending across 648 Senate LDA filings since 2020. Its most frequent lobbying issues are Medicare/Medicaid, Health Issues, Taxation, Copyright/Patent. Lobbying firms used include Amgen, Inc., Todd Strategy Group, Tarplin, Downs & Young, LLC.
Lobbying spending by year
| Year | Reported spend |
|---|---|
| 2026 | $11.3M |
| 2025 | $20.1M |
| 2024 | $16.0M |
| 2023 | $19.2M |
| 2022 | $16.3M |
| 2021 | $16.5M |
See insider trading for AMGN or the Lobbying Heavyweights strategy.
Source: Senate Lobbying Disclosure Act (LD-2) filings. The current year is partial.